PharmaEssentia Corporation
6446
Rang in Aktien
#1441
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktienkurs
$36.89
Marktkapitalisierung
$15.25B
Veränderung (1 Tag)
-1.28%
Veränderung (1 Jahr)
144.12%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategorie
Healthcare
P/S-Verhältnis für PharmaEssentia Corporation (6446)
P/S-Verhältnis zum October 2026 TTM: 23.96
Laut den neuesten Finanzberichten und dem Aktienkurs von PharmaEssentia Corporation beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 23.96. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 22.06.
P/S-Verlauf für PharmaEssentia Corporation von 2010 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 23.96 | 16.52% |
| 2024 | 20.56 | -6.80% |
| 2023 | 22.06 | -53.07% |
| 2022 | 47.01 | -58.98% |
| 2021 | 114.59 | 181.19% |
| 2020 | 40.75 | -46.81% |
| 2019 | 76.61 | -94.54% |
| 2018 | 1.40K | -81.75% |
| 2017 | 7.68K | 27.57% |
| 2016 | 6.02K | 95.48% |
| 2015 | 3.08K | 61.64% |
| 2014 | 1.91K | 276.50% |
| 2013 | 506.34 | -45.75% |
| 2012 | 933.30 | -41.98% |
| 2011 | 1.61K | 237.00% |
| 2010 | 477.29 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -70.54% |
IN
|
